-+=

Astherna is a preclinical-stage RNA therapy company developing treatments for inherited retinal diseases, that affect affecting hundreds of thousands individuals worldwide. The first inherited retinal disease for which Astherna will conduct a clinical trial is Stargardt disease, the most prevalent inherited retinal disease caused by a single gene. For several genetic defects that cause this disease, we have developed a unique therapeutic approach with which we aim to stop the progression of the disease, and prevent individuals from getting blind.

We encourage you to contact us upon interest in Astherna here.

Curious about the people behind Astherna? Read more about our Team.

What is the power of Astherna?

Astherna’s close connection to the academia allows us to stay close to the patients’ perspective and to follow developments in cutting-edge technologies for RNA therapeutics closely. Therefore, Astherna brings a unique platform to bring novel RNA therapeutics to patients with Stargardt disease, and in the future for other inherited retinal diseases

What are the key strong points of Astherna's RNA therapy for STGD1?

  • It is aimed to stop progression of Stargardt disease caused by a relatively common severe ABCA4 mutation. It thus addresses the root cause of the problem in a genetic disease. There is currently no treatment available for these patients, who ultimately become blind.
  • It is based on a unique technology of restoring RNA splicing defects. Ex-vivo proof of concept has currently been achieved for several AON candidates.
  • The first AON therapy paves the way for following therapeutics for other ABCA4 mutations and mutations in other genes in a discovery pipeline.

What are we currently working on?

Currently, we are selecting and further developing our lead AON molecule, based on the best efficacy and safety profiles, besides suitability for manufacturing. Moreover, by gathering and analyzing data on the natural course of Stargardt disease in an academic collaboration with the Radboudumc, we work on innovative approaches for cohort selection and clinical trial designs.

Back To Top